vs
QuidelOrtho Corp（QDEL）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是Reddit, Inc.的1.1倍（$699.9M vs $663.0M），Reddit, Inc.净利率更高（30.8% vs -104.7%，领先135.5%），Reddit, Inc.同比增速更快（69.0% vs -3.7%），Reddit, Inc.自由现金流更多（$311.0M vs $-94.7M），过去两年Reddit, Inc.的营收复合增速更高（53.6% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
QDEL vs RDDT — 直观对比
营收规模更大
QDEL
是对方的1.1倍
$663.0M
营收增速更快
RDDT
高出72.7%
-3.7%
净利率更高
RDDT
高出135.5%
-104.7%
自由现金流更多
RDDT
多$405.7M
$-94.7M
两年增速更快
RDDT
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $663.0M |
| 净利润 | $-733.0M | $204.0M |
| 毛利率 | — | 100.0% |
| 营业利润率 | -100.7% | 0.0% |
| 净利率 | -104.7% | 30.8% |
| 营收同比 | -3.7% | 69.0% |
| 净利润同比 | -3583.4% | 680.0% |
| 每股收益（稀释后） | $-10.78 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELRDDT
| Q1 26 | — | $663.0M | ||
| Q4 25 | — | $725.6M | ||
| Q3 25 | $699.9M | $584.9M | ||
| Q2 25 | $613.9M | $499.6M | ||
| Q1 25 | $692.8M | $392.4M | ||
| Q4 24 | $707.8M | $427.7M | ||
| Q3 24 | $727.1M | $348.4M | ||
| Q2 24 | $637.0M | $281.2M |
净利润QDELRDDT
| Q1 26 | — | $204.0M | ||
| Q4 25 | — | $251.6M | ||
| Q3 25 | $-733.0M | $162.7M | ||
| Q2 25 | $-255.4M | $89.3M | ||
| Q1 25 | $-12.7M | $26.2M | ||
| Q4 24 | $-178.4M | $71.0M | ||
| Q3 24 | $-19.9M | $29.9M | ||
| Q2 24 | $-147.7M | $-10.1M |
毛利率QDELRDDT
| Q1 26 | — | 100.0% | ||
| Q4 25 | — | 91.9% | ||
| Q3 25 | — | 91.0% | ||
| Q2 25 | — | 90.8% | ||
| Q1 25 | — | 90.5% | ||
| Q4 24 | — | 92.6% | ||
| Q3 24 | — | 90.1% | ||
| Q2 24 | — | 89.5% |
营业利润率QDELRDDT
| Q1 26 | — | 0.0% | ||
| Q4 25 | — | 31.9% | ||
| Q3 25 | -100.7% | 23.7% | ||
| Q2 25 | -29.4% | 13.6% | ||
| Q1 25 | 4.7% | 1.0% | ||
| Q4 24 | -14.2% | 12.4% | ||
| Q3 24 | 2.1% | 2.0% | ||
| Q2 24 | -18.4% | -11.0% |
净利率QDELRDDT
| Q1 26 | — | 30.8% | ||
| Q4 25 | — | 34.7% | ||
| Q3 25 | -104.7% | 27.8% | ||
| Q2 25 | -41.6% | 17.9% | ||
| Q1 25 | -1.8% | 6.7% | ||
| Q4 24 | -25.2% | 16.6% | ||
| Q3 24 | -2.7% | 8.6% | ||
| Q2 24 | -23.2% | -3.6% |
每股收益（稀释后）QDELRDDT
| Q1 26 | — | $1.01 | ||
| Q4 25 | — | $1.24 | ||
| Q3 25 | $-10.78 | $0.80 | ||
| Q2 25 | $-3.77 | $0.45 | ||
| Q1 25 | $-0.19 | $0.13 | ||
| Q4 24 | $-2.54 | $4.76 | ||
| Q3 24 | $-0.30 | $0.16 | ||
| Q2 24 | $-2.20 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $1.4B |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $3.2B |
| 总资产 | $5.7B | $3.5B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资QDELRDDT
| Q1 26 | — | $1.4B | ||
| Q4 25 | — | $953.6M | ||
| Q3 25 | $98.1M | $911.7M | ||
| Q2 25 | $151.7M | $734.1M | ||
| Q1 25 | $127.1M | $635.7M | ||
| Q4 24 | $98.3M | $562.1M | ||
| Q3 24 | $143.7M | $515.9M | ||
| Q2 24 | $107.0M | $468.0M |
总债务QDELRDDT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
股东权益QDELRDDT
| Q1 26 | — | $3.2B | ||
| Q4 25 | — | $2.9B | ||
| Q3 25 | $2.0B | $2.6B | ||
| Q2 25 | $2.8B | $2.4B | ||
| Q1 25 | $3.0B | $2.2B | ||
| Q4 24 | $3.0B | $2.1B | ||
| Q3 24 | $3.2B | $2.0B | ||
| Q2 24 | $3.2B | $1.9B |
总资产QDELRDDT
| Q1 26 | — | $3.5B | ||
| Q4 25 | — | $3.2B | ||
| Q3 25 | $5.7B | $2.9B | ||
| Q2 25 | $6.4B | $2.6B | ||
| Q1 25 | $6.5B | $2.4B | ||
| Q4 24 | $6.4B | $2.3B | ||
| Q3 24 | $6.8B | $2.2B | ||
| Q2 24 | $6.7B | $2.1B |
负债/权益比QDELRDDT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | — |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $311.0M |
| 自由现金流率自由现金流/营收 | -13.5% | 46.9% |
| 资本支出强度资本支出/营收 | 7.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $868.6M |
8季度趋势，按日历期对齐
经营现金流QDELRDDT
| Q1 26 | — | — | ||
| Q4 25 | — | $266.8M | ||
| Q3 25 | $-45.5M | $185.2M | ||
| Q2 25 | $-46.8M | $111.3M | ||
| Q1 25 | $65.6M | $127.6M | ||
| Q4 24 | $63.7M | $90.0M | ||
| Q3 24 | $117.9M | $71.6M | ||
| Q2 24 | $-97.9M | $28.4M |
自由现金流QDELRDDT
| Q1 26 | — | $311.0M | ||
| Q4 25 | — | $263.6M | ||
| Q3 25 | $-94.7M | $183.1M | ||
| Q2 25 | $-84.3M | $110.8M | ||
| Q1 25 | $9.4M | $126.6M | ||
| Q4 24 | $16.5M | $89.2M | ||
| Q3 24 | $71.4M | $70.3M | ||
| Q2 24 | $-133.2M | $27.2M |
自由现金流率QDELRDDT
| Q1 26 | — | 46.9% | ||
| Q4 25 | — | 36.3% | ||
| Q3 25 | -13.5% | 31.3% | ||
| Q2 25 | -13.7% | 22.2% | ||
| Q1 25 | 1.4% | 32.3% | ||
| Q4 24 | 2.3% | 20.8% | ||
| Q3 24 | 9.8% | 20.2% | ||
| Q2 24 | -20.9% | 9.7% |
资本支出强度QDELRDDT
| Q1 26 | — | — | ||
| Q4 25 | — | 0.4% | ||
| Q3 25 | 7.0% | 0.4% | ||
| Q2 25 | 6.1% | 0.1% | ||
| Q1 25 | 8.1% | 0.2% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 6.4% | 0.4% | ||
| Q2 24 | 5.5% | 0.4% |
现金转化率QDELRDDT
| Q1 26 | — | — | ||
| Q4 25 | — | 1.06× | ||
| Q3 25 | — | 1.14× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 4.88× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 2.40× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
RDDT
暂无分部数据
